Physician profile
Charles Mcclean
NPI 1144272071
$3,756.59
in general payments reported to CMS, 2019-2025
17 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $105 · 2022: $376 · 2023: $2,134 · 2024: $447 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Consulting Fee: $1,380 · Education: $37.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.33 |
| Consulting Fee | $1,380.00 |
| Education | $37.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,415.12 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $394.23 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $362.84 | 2019-2025 | Nuzyra |
| Shionogi INC | $313.12 | 2020-2025 | Fetroja |
| Smith+Nephew, INC. | $291.52 | 2019-2024 | Grafix Pl, Collagenase Santyl |
| Abbvie INC. | $262.66 | 2022-2025 | |
| Cumberland Pharmaceuticals, INC. | $254.19 | 2023-2025 | Vibativ |
| Octapharma USA, INC. | $126.93 | 2022-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Melinta Therapeutics, LLC | $90.63 | 2019-2024 | Kimyrsa, Rezzayo, Orbactiv |
| Insmed, INC. | $56.22 | 2022-2023 | Arikayce |
| Tactile Systems Technology INC | $47.24 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Reprise Biomedical, INC. | $36.82 | 2023-2025 | Miro3d |
| Kci USA, INC. | $30.35 | 2020-2023 | Activ.A.C. |
| Pfizer INC. | $24.48 | 2024 | |
| Aimmune Therapeutics, INC. | $21.46 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.91 | 2019 | |
| Novo Nordisk INC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.